Candida krusei fungaemia: antifungal susceptibility and clinical presentation of an uncommon entity during 15 years in a single general hospital.
about
Candida krusei, a multidrug-resistant opportunistic fungal pathogen: geographic and temporal trends from the ARTEMIS DISK Antifungal Surveillance Program, 2001 to 2005Antifungal efficacy during Candida krusei infection in non-conventional models correlates with the yeast in vitro susceptibility profileA cluster of Candida krusei infections in a haematological unit.Protective effect of a novel antifungal peptide derived from human chromogranin a on the immunity of mice infected with Candida krusei.Surveillance study of species distribution, antifungal susceptibility and mortality of nosocomial candidemia in a tertiary care hospital in China.Voriconazole in the management of nosocomial invasive fungal infections.Determination of antifungal susceptibility patterns among the clinical isolates of Candida speciesAntiproliferative effect and characterization of a novel antifungal peptide derived from human Chromogranin A.Anti-candidal activity of a novel peptide derived from human chromogranin A and its mechanism of action against Candida kruseiCandida krusei: biotechnological potentials and concerns about its safety.The Candida pathogenic species complex.Risk factors for fluconazole-resistant candidemia.Comparison of the clinical risk factors between Candida albicans and Candida non-albicans species for bloodstream infection.Strain typing and determination of population structure of Candida krusei by multilocus sequence typing.In vivo and in vitro acquisition of resistance to voriconazole by Candida krusei.In vitro activities of echinocandins against Candida krusei determined by three methods: MIC and minimal fungicidal concentration measurements and time-kill studies.Photodynamic inactivation of four Candida species induced by photogem(®).Candidaemia associated with decreased in vitro fluconazole susceptibility: is Candida speciation predictive of the susceptibility pattern?Novel antifungal activity of purpurin against Candida species in vitro.Factors associated with candidemia caused by non-albicans Candida species versus Candida albicans in the intensive care unit.Photodynamic antimicrobial chemotherapy (PACT) using toluidine blue inhibits both growth and biofilm formation by Candida krusei.ERG11 mutations and upregulation in clinical itraconazole-resistant isolates of Candida krusei.CGA-N12, a peptide derived from chromogranin A, promotes apoptosis of Candida tropicalis by attenuating mitochondrial functions.
P2860
Q28260910-49655B0D-11ED-43B7-8395-9D1C35C99F9EQ28489096-B5B53D90-CF0B-47B6-9B45-5FE9783D0091Q33294780-3AF70147-68D5-422C-8C11-2CD7D5247BB1Q33724155-DF427658-79DC-4F48-8170-E24E6DED3BB2Q34856747-064C749B-5908-49F3-990D-BE761124A9C9Q35166823-431CBE9E-D0AD-4A57-9DAB-F53489D2E5EDQ35646997-46871BD9-9087-4CF1-88A7-2335BD3B7505Q36334389-75A3DD50-AFBB-4FF0-9D41-F7AD88EB5DAFQ36335705-158A8E01-3846-4415-892E-75FB53D9F19BQ38028552-87D774FC-C841-4FDB-8DD0-43972CE345ABQ38245727-A0A7090D-3245-4569-BC4A-E501186D83DEQ39934814-F7C7C693-AE4B-46DF-B8EE-258F24263515Q40163927-2F94E463-CEAC-4322-A172-F9C3B9129B79Q41819710-55AC257D-C359-4BE0-8923-31E7C188C35CQ42109755-C7D35C3C-0AC1-47F2-A747-472F6705393AQ42111638-BDEBE9EE-951C-4865-8F4F-1A86DFF55A55Q42593820-9BB3D6CC-9604-41C8-83B0-F82290877512Q43079484-426FC968-83C2-415A-9CB2-ABDC694C0BA5Q43099651-A7F42573-B119-4CA6-8AC2-A550D4C7BA57Q43737173-72C75CF5-14FF-4366-8ED8-C09B9089F0B5Q50053143-260F68BE-E799-409C-BF67-5E3B683AC3D8Q51512831-6649BF14-EFB8-480D-AA96-0DD6050DCD4DQ52646178-3B8725C7-F47F-4AD2-BC6A-891D2FD4283B
P2860
Candida krusei fungaemia: antifungal susceptibility and clinical presentation of an uncommon entity during 15 years in a single general hospital.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
Candida krusei fungaemia: anti ...... in a single general hospital.
@en
Candida krusei fungaemia: anti ...... in a single general hospital.
@nl
type
label
Candida krusei fungaemia: anti ...... in a single general hospital.
@en
Candida krusei fungaemia: anti ...... in a single general hospital.
@nl
prefLabel
Candida krusei fungaemia: anti ...... in a single general hospital.
@en
Candida krusei fungaemia: anti ...... in a single general hospital.
@nl
P2093
P2860
P356
P1476
Candida krusei fungaemia: anti ...... in a single general hospital.
@en
P2093
Luis Alcalá
Mar Sánchez-Somolinos
Marta Rodríguez-Créixems
Patricia Muñoz
Teresa Peláez
P2860
P304
P356
10.1093/JAC/DKH532
P407
P50
P577
2005-01-13T00:00:00Z